FLLL32 from MedChemExpress

Product Specs
ItemFLLL32
CompanyMedChemExpress
Price $85.00Supplier Page View Company Product Page
Catalog NumberHY-100544
Quantity10 mM * 1 mL
ApplicationsBioactivity, Structure and function analysis, ELISA, SDS-PAGE, Western blotting
Purity99.78%
TypeChemical
Molecular Weight464.55
FormulaC₂₈H₃₂O₆
Research AreaCancer

1 Deer Park Drive, Suite F

MONMOUTH JUNCTION, NJ 08852

United States

Phone: US Tel: 609-228-6898
US Fax: 609-228-5909
EU Tel: +4686500910

Email: sales@medchemexpress.com
eu.sales@MedChemExpress.com

(1) PD-L1 as a Potential Inducer for NF-κB Pathway Activation in M1-Type Macrophages During Sepsis: An Integrated Analysis Based on GEO Public Database and Multi-Omics DataJ Inflamm ResJanuary 9, 2026Mu Yuan, Tong Jin, Qing Zhao, Lixing TianUSA). AP-1 inhibitor PNRI-299 (HY-15131), NF-κB inhibitor PDTC (HY-18738) and STAT3 inhibitor FLLL32 (HY-100544) were obtained from MCE (Monmouth Junction, NJ, USA). Cell Culture The THP-1 cell line was obtained

(2) PD-L1 as a Potential Inducer for NF-κB Pathway Activation in M1-Type Macrophages During Sepsis: An Integrated Analysis Based on GEO Public Database and Multi-Omics DataJournal of Inflammation ResearchJanuary 9, 2026Mu Yuan, Tong Jin, Qing Zhao, Lixing TianUSA). AP-1 inhibitor PNRI-299 (HY-15131), NF-κB inhibitor PDTC (HY-18738) and STAT3 inhibitor FLLL32 (HY-100544) were obtained from MCE (Monmouth Junction, NJ, USA). Cell Culture The THP-1 cell line was obtained

(3) Dual Role of Necroptosis in Cervical Cancer: Promoting Tumor Aggression and Modulating the Immune Microenvironment via the JAK2-STAT3 PathwayJournal of CancerAugust 13, 2024Fangfang Xu, Yingjun Ye, Yueqing Gao, Shaohua Xu(Figure 2F) whereas they were found to decrease with the treatment of NSA (Figure 2G). FLLL32 (MCE, HY-100544) was a specific inhibitor of the JAK2-STAT3 pathway, JAK2, STAT3 and p-STAT3 were found to be inhibited

(5) Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cellsCancer researchMarch 15, 2010Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, Pandit B, Ihnat MA, Shenoy SS, Kulp S, et al.

Description